The Knee Arthrodesis Implants market size is projected to reach $2.1 billion by 2033, advancing at a 4.8% CAGR from an estimated $1.65 billion in 2026. Growth is underpinned by a 17% spike in revision TKA volume, rising antimicrobial-resistant periprosthetic infections, and surgeon adoption of titanium-based, patient-specific 3-D printed nails that shorten fusion time by 25%. North America commands 41% of global revenue on high ASPs and bundled-payment penetration, while APAC is the fastest-expanding region (>6% CAGR) driven by medical tourism in India and Thailand. Competitive intensity is sharpening as niche extremity players (e.g., Zimmer Biomet, Smith+Nephew, OrthoMed, Marle Group) acquire small CAD/CAM machine shops to secure titanium rod supply and accelerate PMA pathway differentiation. Regulatory scrutiny is pivoting toward antimicrobial surface coatings, with the FDA’s 2025 draft guidance demanding real-world evidence of infection risk reduction >30%, pushing suppliers into nano-silver / iodine-doped hydroxyapatite R&D partnerships. Supply-chain resilience is now C-suite priority after 2024’s titanium rod shortage inflated average selling prices 9–11%; OEMs are dual-sourcing from Japan and U.S. mills and negotiating 3-year price caps with GPOs to protect margin in an increasingly value-driven procurement landscape.